Evidence map›Paper›PMID 38757305›Full record

ArticleClinical pharmacology and therapeutics2024

Trust in the Food and Drug Administration: A National Survey Study.

William B Feldman, Leah Z Rand, Daniel Carpenter, Massimiliano Russo, Anushka Bhaskar, Zhigang Lu, Eric G Campbell, Jonathan Darrow, Aaron S Kesselheim

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William B FeldmanDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-3467-5869
Leah Z RandDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-3262-1584
Daniel CarpenterDepartment of Government, Faculty of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.
Massimiliano RussoDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-4953-9341
Anushka BhaskarDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Zhigang LuDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Eric G CampbellUniversity of Colorado School of Medicine, Aurora, Colorado, USA.
Jonathan DarrowDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8867-2666

Funding

Improving COPD Outcomes: Using Real-World Data to Analyze Treatment Effectiveness, Safety, and AdherenceK08HL163246 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI William Brand Feldman · 2023 to 2026
$643k
NHLBI NIH HHS K08 HL163246
6 · The paper itself

Abstract

Building trust in public health agencies like the US Food and Drug Administration (FDA) has become a key government priority. Understanding the roots of FDA mistrust is important if the agency is to develop targeted messaging and reforms aimed at building confidence in the agency. We conducted a survey of 2,021 respondents in the US probing attitudes toward the FDA. The primary outcome was FDA trust, defined as the mean score that each respondent assigned to the FDA across four prespecified axes: (1) competence and effectiveness; (2) commitment to acting in the best interests of the American public; (3) abiding by the rules and regulations set forth by policy or law; and (4) expertise in health, science, and medicine. On multivariable ordinal logistic regression, FDA mistrust was associated with female gender (odds ratio [OR] = 0.74, 95% confidence interval [CI] 0.62-0.88), rural community (OR 0.85, 95% CI 0.75-0.96), conservative political views (OR 0.77, 95% CI 0.74-0.81), worse self-reported health (OR 0.89, 95% CI 0.80-0.98), lower satisfaction with health care received (OR 0.63, 95% CI 0.56-0.71), less attention to health and science news (OR 0.72, 95% CI 0.64-0.80), and not having children under the age of 18 (OR 0.72, 95% CI 0.60-0.86). These findings underscore the challenges faced by US political leaders in convincing a heterogeneous American public to trust the FDA. The FDA should develop and deploy targeted outreach strategies to populations with lower levels of trust and strengthen internal processes that minimize biases and ensure sound decision-making.

Indexed as

TrustUnited States Food and Drug AdministrationAdolescentAdultAgedFemaleHumansMaleMiddle AgedPublic OpinionSurveys and QuestionnairesUnited StatesYoung Adult

Identifiers

PMID38757305
PMCPMC11251860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.